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Summary 
Psoriatic skin is characterized by microvascular hyperpermeability and angioproliferation, but 
the mechanisms responsible are unknown. We report here that the hyperplastic epidermis of 
psoriatic skin expresses strikingly increased amounts of vascular permeability factor (VPF; vascular 
endothelial  growth  factor),  a  selective endothelial cell mitogen that  enhances microvascular 
permeability. Moreover, two VPF receptors, kdr and fit-l, are overexpressed by papillary dermal 
microvascular endothelial cells. Transforming growth factor ot (TGF-o  0, a cytokine that is also 
overexpressed  in  psoriatic  epidermis,  induced  VPF  gene  expression  by  cultured  epidermal 
keratinocytes. VPF secreted by TGF-c~-stimulated keratinocytes was bioactive, as demonstrated 
by its mitogenic effect on dermal microvascular endothelial cells in vitro. Together, these findings 
suggest that TGF-ot regulates VPF expression in psoriasis by an autocrine mechanism, leading 
to vascular hyperpermeability and angiogenesis. Similar mechanisms may operate in tumors and 
in healing skin wounds which also commonly express both VPF and TGF-ol. 
p!  soriasis  is a common, chronic skin disease characterized 
by  recurrent  erythematous  skin  plaques  that  exhibit 
epidermal hyperplasia, a variable inflammatory cell infiltrate, 
and abnormalities of the papillary dermal vasculature (1-4). 
Microvessels in the papillary dermis of psoriatic plaques are 
elongate, dilated, and hyperpermeable (5, 6) and more closely 
resemble postcapillary  venules than  the capillary  loops  of 
normal skin (7, 8). Whereas vascular changes may precede 
inflammatory cell infiltration in developing psoriatic plaques, 
and may reappear before clinical relapse (9-11),  there is in- 
creasing evidence that epidermal alterations precede capillary 
leakiness and vascular anomalies in the development of psoriatic 
skin lesions (12).  Moreover, a previous study demonstrated 
that the angiogenic properties of psoriatic skin were associated 
with the epidermis, not the dermis (13). 
Vascular permeability factor (VPF) is a 32-42-kD  glyco- 
sylated protein that is overexpressed by many human and an- 
imal tumors (14-17) and by the epidermis of healing wounds 
(18),  conditions that, like psoriasis,  are associated with en- 
hanced microvascular permeability and angiogenesis. Two tyro- 
sine kinase receptors for VPF, kdr and fit-l, are also overex- 
pressed in the microvessels of tumors that overexpress VPF 
(19-21).  In vivo, VPF enhances microvascular permeability 
with a potency some 50,000 times that of histamine and in- 
duces angiogenesis (22-25). In vitro, VPF is a selective mitogen 
for cultured endothelial cells, hence its alternate name, vas- 
cular endothelial growth factor (26,  27).  We hypothesized 
that a cytokine with these properties might play an impor- 
tant role in the pathogenesis of psoriasis. 
In this report, we demonstrate increased expression of VPF 
mRNA by the hyperplastic epidermis of lesional psoriatic 
skin and increased expression of two VPF receptors in psori- 
atic dermal microvessels. In vitro investigations showed that 
VPF expression and secretion of bioactive VPF by epidermal 
keratinocytes were induced by TGF-o~, a cytokine known to 
be overexpressed in psoriatic epidermis (28, 29). Therefore, 
besides its mitogenic effect on epidermal keratinocytes, TGF-o~ 
likely regulates VPF expression in psoriatic epidermis by an 
autocrine mechanism, leading to increased vascular perme- 
ability and angiogenesis. 
Materials and Methods 
In Situ Hybridization and Immunohistochemistry.  6-ram punch bi- 
opsies were taken, after obtaining informed consent, from the in- 
volved and uninvolved skin of six patients with chronic plaque- 
type psoriasis that had not been treated for a period of at least 6 wk 
and from the normal skin of six healthy volunteers. In situ hybrid- 
ization was performed on 6 #m fresh-frozen tissue sections using 
single-stranded antisense or control sense riboprobes as described 
(20). The VPF probe was prepared from a 204-bp VPF cDNA frag- 
ment isolated from human HT 1080 ceUs (30). Riboprobes for the 
VPF receptors, kdr and fit-l, were prepared from cDNA fragments 
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frozen tissue sections reacted with an affinity-purified  rabbit anti- 
body against a 26-amino acid peptide corresponding to the NH2- 
terminus of human VPF as described (31). The specificity  of this 
antibody has been documented by Western blotting (32). As a nega- 
tive control, primary anti-VPF  antibody was replaced  with an equiva- 
lent concentration of normal rabbit IgG. 
Cell Culture.  Human epidermal keratinocyte cultures were es- 
tablished from normal adult body skin of healthy volunteers and 
propagated in serum-free  keratinocyte  growth medium (KGM) (Clo- 
netics Corp., San Diego, CA) as described (33). Second passage 
keratinocytes  were used in all experiments. Human dermal microvas- 
cular endothelial cells (HDMEC) were isolated from neonatal fore- 
skins after routine circumcisions as described (34) and cultured on 
fibronectin-coated culture dishes in endothelial basal (EBM) (Clo- 
netics Corp.), supplemented with 20% FCS, 1/zg/ml hydrocorti- 
sone acetate, and 10/~M dibutyryl-cAMP (all from Sigma Chem- 
ical Co., St. Louis, MO). 
Northern Blot Analysis.  Total  cellular RNA was extracted from 
confluent, second-passage  keratinocytes  cultured in 100-ram dishes 
for 24 h in KBM without added  growth factors,  with 0.1-100 ng/ml 
recombinant human TGF-c~ (British Biotechnology,  Abington, UK) 
or with 10 ng/ml recombinant human epidermal growth factor 
(EGF; Clonetics Corp.) as described (35). Northern blots were hy- 
bridized with a human VPF cDNA probe (546 bp) obtained by 
reverse transcription-PCR of RNA from human glioblastoma  U-373 
cells, using the oligonucleotide primers 5'-TCCGAATTCGCA- 
CCCATGGCAAGAA-3' and  5'-TTCGAATTCCCTGAGGGA- 
GCTCC-Y. Control hybridization was performed with ribosome- 
associated protein cDNA, 36B4 (36) to demonstrate equivalent 
RNA loading. 
VPF Immunofluorometric Assay.  Confluent second passage ker- 
atinocytes  were cultured in 24-well plates for 48 h in KBM without 
added growth factors, or with added TGF-ot (0.1-100 ng/ml), or 
with TGF-c~ (100 ng/ml) plus 10 #g/ml rabbit anti-EGF receptor 
antibody (UBI, Lake Placid, NY). VPF was quantitated in condi- 
tioned  media (CM) by a modified two-site,  time-resolved im- 
munofluorometric assay (37) using a polyclonal antibody against 
recombinant human VPF for both capture and detection. Values 
were normalized for total cell numbers after culture. Data are ex- 
pressed as pM VPF/10  s cells. In  these and other  experiments, 
statistical significance  was calculated with the Dunnett multiple 
comparison test. 
Bioassay for Mitogenic Activity of Keratinocyte CM.  CM was 
collected from confluent keratinocyte cultures in 100-mm dishes 
incubated for 48 h in 5 ml KBM medium supplemented with 
100 ng/ml TGF-cr and stored frozen at  -80~  for up to 2 wk. 
As control, medium was added to culture dishes without cells and 
incubated and processed identically.  Second passage HDMEC were 
seeded at 5 x  103 cells/cm  2 in 24-well plates in EBM medium sup- 
plemented with 2% FCS. After 16 h, varying amounts (1-30%) 
of  keratinocyte conditioned or control medium were added to qua- 
druplicate wells for 48 h. 1/xCi/ml methyl-[3H]thymidine  (sp act 
82.4 Ci/mmol; DuPont NEN, Boston, MA) was added during 
the final  6 h of  culture, and the thymidine incorporation into DNA 
was determined as described (38). Data are expressed as a stimula- 
tory index: ratio of net [3H]thymidine  incorporation by HDMEC 
cultured with conditioned or control medium. 
VPFDepletion by Solid Phase lmmunoadsorption.  CM from ker- 
atinocyte cultures treated with 100 ng/ml TGF-a (see above) were 
depleted of  VPF by solid  phase immunoadsorption as described  (32), 
using the same affinity-purified  anti-VPF antibody as for immuno- 
histochemistry, coupled to protein A-Sepharose  beads (Pharmacia, 
Uppsala, Sweden). As a control, CM was depleted of TGF-a with 
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a specific  polyclonal antibody (PeproTech, Rocky Hill, NJ) or in- 
cubated with Sepharose  beads alone. Control medium was treated 
identically.  The capacity  of  these CM to stimulate HDMEC thymi- 
dine incorporation was measured as described above. 
Results and Discussion 
Initial experiments were performed to determine whether 
VPF was overexpressed in psoriatic skin. In situ hybridiza- 
tion (ISH) demonstrated enhanced expression ofVPF mRNA 
in the hyperplastic epidermis of all psoriatic patients biop- 
sied  (Fig.  1 A).  As in healing skin wounds, differentiated 
keratinocytes of the suprabasal layers labeled most intensely, 
but VPF mRNA was also expressed focally  by basal keratino- 
cytes and by rare mononuclear inflammatory cells infiltrating 
the upper dermis. In contrast, little or no VPF mRNA was 
expressed in the epidermis of all normal volunteers (Fig.  1 
C). ISH performed on areas of skin from psoriatic patients 
that appeared clinically normal also revealed focally increased 
expression  of VPF  mRNA.  However,  these biopsies  also 
showed microscopic abnormalities suggestive of early psori- 
atic activity. Consistent with these ISH findings, immuno- 
histochemistry of clinically involved psoriatic skin revealed 
strong  cytoplasmic  staining  for  VPF,  predominantly  in 
suprabasal epidermal keratinocytes (Fig. 1 E). ISH was also 
employed to identify sites of VPF receptor mRNA expres- 
sion. Strong labeling for the mRNAs of both kdr and fit-1 
was observed  in the papillary dermal microvessels of active 
psoriatic lesions (Fig. 1 D). In contrast, little or no receptor 
expression was detected in deeper vessels of psoriatic skin or 
in vessels of normal skin. 
Because increased VPF expression likely contributes to the 
microvascular hyperpermeability and angiogenesis  of tumors 
and healing skin wounds (14-17), we reasoned that a common 
mediator might be responsible for upregulating VPF expres- 
sion in these disorders as well as in psoriasis. A likely candi- 
date was TGF-c~, a cytokine with angiogenic properties in 
vivo (39) and one known to be overexpressed in the epidermis 
of psoriatic skin lesions and of healing skin wounds and in 
many epithelial tumors (28,  29,  40). 
To test the possibility that TGF-ot might regulate VPF ex- 
pression in psoriasis, we performed Northern analyses  on RNA 
extracted from confluent human epidermal keratinocytes, cul- 
tured with or without TGF-ot. VPF mRNA expression was 
upregulated by TGF-ot in a dose-dependent fashion at con- 
centrations i>1 ng/ml (Fig. 2 A). EGF also upregulated VPF 
mRNA  expression  by cultured keratinocytes (Fig.  2 A); 
TGF-ot is structurally related to EGF and reacts with the EGF 
receptor (41,  42). 
To determine whether TGF-a also increased synthesis and 
secretion of VPF protein, we tested keratinocyte CM for VPF 
by immunoassay. After 48  h  of culture in the presence  of 
TGF-c~, keratinocyte CM contained significantly increased 
amounts of immunoreactive VPF protein.  At  100 ng/ml, 
TGF-ot  increased  VPF  levels fivefold,  and  a  statistically 
significant increase was noted with concentrations as low as 
3 ng/ml (Fig. 2 B). This effect was mediated by TGF-ot binding 
to the EGF receptor,  since addition of an anti-EGF receptor 
Overexpression of Vascular Permeability  Factor in Psoriasis Figure  1.  Localization of VPF 
and VPF receptors in histological 
sections of psoriatic and normal skin 
by  ISH  (A-D) and  immuno- 
histochemistry  (E  and  F).  (A) 
Hyperplastic  epidermis of psoriatic 
skin hybridized with a specific 35S- 
antisense riboprobe that recognizes 
all  VPF  isoforms.  Note  intense 
labeling of keratinocytes, especially 
in the suprabasal layers. (B) Control 
hybridization  with  VPF  sense 
riboprobe on  an  adjacent  section 
shows  low background.  (C) Low 
level VPF  mRNA  expression  by 
scattered  keratinocytes  in  normal 
skin hybridized  with VPF antisense 
probe.  (D)  Selective  labeling  of 
microvessels in the papillary  dermis 
of psoriatic skin (arrows) with an- 
tisense probe specific for the VPF 
receptor kdr. Identical labeling (not 
illustrated) was observed with an- 
tisense riboprobe to a second VPF 
endothelial cell receptor,  fit-1. (E) 
Immunohistochemical localization 
of VPF protein in the epidermis of 
lesional psoriatic skin. Note prom- 
inent cytoplasmic staining of ker- 
atinocytes in the suprabasal layers. 
(F)  Negative  immunoperoxidase 
control in which primary anti-VPF 
antibody was replaced with normal 
rabbit IgG. (A-F):  x430. 
Figure  2.  Dose-dependent  increase  of  VPF 
mRNA (A) and protein (B) in human keratino- 
cytes cultured with or without TGF-cx or EGF. 
(A) Northern blot of total RNA (20/~g/lane) ex- 
tracted from confluent keratinocytes  cultured for 
4 h in KBM medium without added growth factors 
(C), with varying concentrations of TGF-cr  or 
with 10 ng/ml EGF. The blot was hybridized with 
a VPF cDNA probe; control hybridization with 
ribosome-associated protein cDNA, 36B4 demon- 
strates equivalent RNA loading. (B) VPF protein 
in the CM of keratinocytes cultured for 48 h in 
KBM medium alone (O), or supplemented with 
TGF-cx (0.1-100 ng/ml, 0), or supplemented with 
100 ng/ml TGF-cz plus 10/~g/ml rabbit anti-EGF 
receptor antibody (gz). Data are expressed as pM 
VPF per 105 cells (mean  +- SD; n  =  3). p <0.05 
for 3 ng/ml, p  <0.01  for 10-100  ng/ml. 
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Figure 3.  (A) Stimulation of DNA syn- 
thesis in cultured human dermal microvascular 
endothelial  cells (HDMEC) by conditioned 
medium (CM) from keratinocytes  cultured 48 h 
in serum-free medium supplemented with 100 
ng/ml TGF-c~. DNA synthesis is expressed as 
a stimulatory index (mean _  SD): ratio of net 
thymidine incorporation by HDMEC cultured 
with added conditioned/control  medium (n = 
4). (B) Depletion of VPF by immunoadsorp- 
tion significantly suppressed the stimulatory 
effect of 10% CM from TGF-c~-treated ker- 
atinocytes on HDMEC [3H]thymidine incor- 
poration (p <0.01).  Analogous  depletion  of 
TGF-o~  or incubating CM with Sepharose  beads 
alone (*) did not significantly  alter the stimula- 
tory effect of keratinocyte CM. Data are ex- 
pressed as a stimulatory index as described  above 
(mean _+ SD): ratio of net thymidine  incorpo- 
ration by HDMEC cultured with added 10% 
conditioned/control medium (n  =  4). 
antibody inhibited VPF induction by TGF-o~ (Fig.  2 B). 
Though  somewhat less  effective,  EGF  also  increased  the 
amount of VPF released by cultured keratinocyte (data not 
shown). Inasmuch as TGF-c~ and EGF receptors (but not EGF 
itself) are overexpressed  in psoriatic skin (28,  29, 43),  our 
findings suggest that TGF-c~ may stimulate VPF synthesis 
and secretion by epidermal keratinocytes in psoriasis.  This 
is further supported by the almost identical localization of 
keratinocytes expressing VPF mKNA and TGF-cr mRNA 
(44) within the epidermis. In contrast, neither IL-6 nor -8, 
other cytokines increased in lesional psoriatic epidermis, modu- 
lated VPF levels in keratinocyte CM. 
The VPF identified in keratinocyte CM by immunoassay 
was biologically active, as measured by its capacity to stimu- 
late thymidine incorporation in cultured HDMEC. HDMEC 
strongly express VPF receptors and proliferate in response 
to graded doses ofVPF (Detmar, M., unpublished data). CM 
obtained from TGF-cc-treated keratinocyte cultures was po- 
tently mitogenic for HDMEC in a concentration-dependent 
fashion (Fig. 3 A). Because the mitogenic effect of keratino- 
cyte CM might have resulted from secreted products other 
than VPF, possibly including TGF-oe itself, additional experi- 
ments were performed to demonstrate specificity. Depletion 
of VPF by specific antibodies removed more than 80%  of 
the endothelial cell mitogenic activity present in CM derived 
from  TGF-cr  keratinocyte  cultures.  In  contrast, 
depleting CM of TGF-~ was without effect (Fig.  3 B). 
Our findings indicate that both VPF and two of its receptors 
are strikingly overexpressed  in psoriatic skin and, by this mech- 
anism, likely induce the increased numbers of hyperperme- 
able blood vessels required to meet the increased nutritional 
needs of the hyperplastic psoriatic epidermis.  It remains to 
be established whether additional angiogenic factors also con- 
tribute to the microvascular alterations in psoriasis. Whereas 
production ofplatelet-derived growth factor (PDGF) and basic 
fibroblast growth factor (bFGF) by epidermal keratinocytes 
in vitro, as well as increased expression of PDGF receptors 
by dermal psoriatic vessels, have  been previously demonstrated 
(45, 46), elevated levels of these factors in psoriatic skin have 
not been reported. Moreover,  neither PDGF nor bFGF is 
known to increase microvascular  permeability. 
Our in vitro findings indicate that TGF-c~ potently up- 
regulates VPF expression in epidermal keratinocytes. Because 
TGF-oe and the EGF receptor with which it interacts are also 
upregulated in psoriatic epidermis (28,  29, 43),  it is likely 
that TGF-oe, in addition to its mitogenic effect on epidermal 
keratinocytes,  upregulates VPF  expression  in  psoriasis  by 
an autocrine mechanism. These findings have potential sig- 
nificance for, in addition to psoriasis, the pathogenesis of the 
vascular hyperpermeability and angiogenesis that characterize 
many tumors and healing wounds, conditions in which VPF, 
TGF-oe, and their receptors are also overexpressed (14-20, 
40, 43). 
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